Skip to main content
Top
Published in: The International Journal of Cardiovascular Imaging 4/2012

01-04-2012 | Original Paper

Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging

Authors: Jeong Rang Park, Jin-Oh Choi, Hye Jin Han, Sung-A Chang, Sung-Ji Park, Sang-Chol Lee, Yeon Hyeon Choe, Seung Woo Park, Jae K. Oh

Published in: The International Journal of Cardiovascular Imaging | Issue 4/2012

Login to get access

Abstract

Whether the left ventricular (LV) mass index (LVMI) and LV volumetric parameters are associated independently with natriuretic peptide levels is unclear in hypertrophic cardiomyopathy (HCM). Therefore, we investigated which parameters have an independent relationship with N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in HCM patients using echocardiography and cardiac magnetic resonance imaging (CMR). A total of 103 patients with HCM (82 men, age 53 ± 12 years) were evaluated. Echocardiographic evaluations included left atrial volume index (LAVI) and early diastolic mitral inflow E velocity to early annular Ea velocity ratio (E/Ea). LVMI, maximal wall thickness and LV volumetric parameters were measured using CMR. The median value of NT-proBNP level was 387.0 pg/ml. The mean NT-proBNP level in patients with non-apical HCM (n = 69; 36 patients with asymmetric septal hypertrophy, 11 with diffuse, and 22 with mixed type) was significantly higher than in those with apical HCM (n = 34, P < 0.001). NT-proBNP level was negatively correlated with LV end-diastolic volume (LVEDV) (r = −0.263, P = 0.007) and positively with LVMI (r = 0.225, P = 0.022) and maximal wall thickness (r = 0.495, P < 0.001). Among the echocardiographic variables, LAVI (r = 0.492, P < 0.001) and E/Ea (r = 0.432, P < 0.001) were correlated with NT-proBNP. On multivariable analysis, non-apical HCM, increased maximal wall thickness and LAVI were independently related with NT-proBNP. Severity of LV hypertrophy and diastolic parameters might be important in the elevation of NT-proBNP level in HCM. Therefore, further evaluation of these parameters in HCM might be warranted.
Literature
1.
go back to reference Hasegawa K, Fujiwara H, Doyama K et al (1993) Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88:372–380PubMedCrossRef Hasegawa K, Fujiwara H, Doyama K et al (1993) Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88:372–380PubMedCrossRef
2.
go back to reference Arteaga E, Araujo AQ, Buck P, Ianni BM, Rabello R, Mady C (2005) Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 150:1228–1232PubMedCrossRef Arteaga E, Araujo AQ, Buck P, Ianni BM, Rabello R, Mady C (2005) Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 150:1228–1232PubMedCrossRef
3.
go back to reference Brito D, Matias JS, Sargento L, Cabral MJ, Madeira HC (2004) Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol 23:1557–1582PubMed Brito D, Matias JS, Sargento L, Cabral MJ, Madeira HC (2004) Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol 23:1557–1582PubMed
4.
go back to reference Maron BJ, Tholakanahalli VN, Zenovich AG et al (2004) Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109:984–989PubMedCrossRef Maron BJ, Tholakanahalli VN, Zenovich AG et al (2004) Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109:984–989PubMedCrossRef
5.
go back to reference Nishigaki K, Tomita M, Kagawa K et al (1996) Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 28:1234–1242PubMedCrossRef Nishigaki K, Tomita M, Kagawa K et al (1996) Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 28:1234–1242PubMedCrossRef
6.
go back to reference Panou FK, Kotseroglou VK, Lakoumentas JA et al (2006) Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Hellenic J Cardiol 47:344–351PubMed Panou FK, Kotseroglou VK, Lakoumentas JA et al (2006) Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Hellenic J Cardiol 47:344–351PubMed
7.
go back to reference Kim SW, Park SW, Lim SH et al (2006) Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol 29:155–160PubMedCrossRef Kim SW, Park SW, Lim SH et al (2006) Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol 29:155–160PubMedCrossRef
8.
go back to reference Caselli S, Pelliccia A, Maron M et al (2008) Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hypertrophy by means of three-dimensional echocardiography. Am J Cardiol 102:616–620PubMedCrossRef Caselli S, Pelliccia A, Maron M et al (2008) Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hypertrophy by means of three-dimensional echocardiography. Am J Cardiol 102:616–620PubMedCrossRef
9.
go back to reference Magga J, Sipola P, Vuolteenaho O et al (2008) Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene. Am J Cardiol 101:1185–1190PubMedCrossRef Magga J, Sipola P, Vuolteenaho O et al (2008) Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene. Am J Cardiol 101:1185–1190PubMedCrossRef
11.
go back to reference Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785–789PubMedCrossRef Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785–789PubMedCrossRef
12.
go back to reference Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367PubMed Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367PubMed
13.
go back to reference Thaman R, Esteban MT, Barnes S et al (2006) Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 98:515–519PubMedCrossRef Thaman R, Esteban MT, Barnes S et al (2006) Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 98:515–519PubMedCrossRef
14.
go back to reference Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y (2006) Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 98:1504–1506PubMedCrossRef Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y (2006) Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 98:1504–1506PubMedCrossRef
15.
go back to reference Mizuno Y, Yoshimura M, Harada E et al. (2000) Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 86:1036–1040, A11 Mizuno Y, Yoshimura M, Harada E et al. (2000) Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 86:1036–1040, A11
16.
go back to reference Murakami Y, Shimada T, Inoue S et al (2002) New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol 18:1294–1300PubMed Murakami Y, Shimada T, Inoue S et al (2002) New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol 18:1294–1300PubMed
17.
go back to reference Shim CY, Ha JW, Choi EY et al (2009) Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy. Korean Circ J 39:519–524PubMedCrossRef Shim CY, Ha JW, Choi EY et al (2009) Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy. Korean Circ J 39:519–524PubMedCrossRef
18.
go back to reference Maron BJ, Spirito P (1998) Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 81:1339–1344PubMedCrossRef Maron BJ, Spirito P (1998) Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 81:1339–1344PubMedCrossRef
19.
go back to reference Binder J, Ommen SR, Chen HH, Ackerman MJ, Tajik AJ, Jaffe AS (2007) Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol 15(100):712–714 Binder J, Ommen SR, Chen HH, Ackerman MJ, Tajik AJ, Jaffe AS (2007) Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol 15(100):712–714
20.
go back to reference Sakamoto T (2001) Apical hypertrophic cardiomyopathy (apical hypertrophy): an overview. J Cardiol 37(Suppl 1):161–178 Sakamoto T (2001) Apical hypertrophic cardiomyopathy (apical hypertrophy): an overview. J Cardiol 37(Suppl 1):161–178
21.
go back to reference Das SR, Drazner MH, Dries DL et al (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112:2163–2168PubMedCrossRef Das SR, Drazner MH, Dries DL et al (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112:2163–2168PubMedCrossRef
22.
go back to reference Horwich TB, Hamilton MA, Fonarow GC (2006) B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47:85–90PubMedCrossRef Horwich TB, Hamilton MA, Fonarow GC (2006) B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47:85–90PubMedCrossRef
23.
go back to reference Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982PubMedCrossRef Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982PubMedCrossRef
24.
go back to reference Grothues F, Smith GC, Moon JC et al (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90:29–34PubMedCrossRef Grothues F, Smith GC, Moon JC et al (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90:29–34PubMedCrossRef
Metadata
Title
Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging
Authors
Jeong Rang Park
Jin-Oh Choi
Hye Jin Han
Sung-A Chang
Sung-Ji Park
Sang-Chol Lee
Yeon Hyeon Choe
Seung Woo Park
Jae K. Oh
Publication date
01-04-2012
Publisher
Springer Netherlands
Published in
The International Journal of Cardiovascular Imaging / Issue 4/2012
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-011-9876-4

Other articles of this Issue 4/2012

The International Journal of Cardiovascular Imaging 4/2012 Go to the issue

Case-in-Point

Double trouble